



(51) International Patent Classification:

C07K 14/47 (2006.01) *C07K 14/725* (2006.01)
A61K 35/17 (2015.01) *C12N 5/0783* (2010.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/048786

(22) International Filing Date:

02 September 2021 (02.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/074,747 04 September 2020 (04.09.2020) US

(71) Applicant: **THE UNITED STATES OF AMERICA,
 AS REPRESENTED BY THE SECRETARY, DE-
 PARTMENT OF HEALTH AND HUMAN SERVICES**
 [US/US]; Office of Technology Transfer, National Insti-
 tutes of Health, 6011 Executive Boulevard, Suite 325, MSC
 7660, Bethesda, Maryland 20892-7660 (US).

(72) Inventors: **KIM, Sanghyun**; 11351 Woodglen Drive,
 North Bethesda, Maryland 20852 (US). **ZACHARAKIS,
 Nikolaos**; 113 Ellington Boulevard, Gaithersburg, Mary-
 land 20878 (US). **ROSENBERG, Steven A.**; 10104 Iron
 Gate Road, Potomac, Maryland 20854 (US).

(74) Agent: **LAWLEY, Stephanie M.** et al.; LEYDIG, VOIT
 & MAYER, Two Prudential Plaza, Suite 4900, 180 North
 Stetson Avenue, Chicago, Illinois 60601 (US).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
 NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
 SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53




Fig. 3D

(57) Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53^{R273C} or human p53^{Y220C}. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

14 April 2022 (14.04.2022)